CME Group: Quality Growth With A Defensive Profile

CME Group is rated Buy, supported by record results and a resilient, defensible futures franchise. CME's moat is anchored in open interest and margin efficiencies, not just market share, insulating it from FMX's cash bond competition. Three underappreciated growth drivers: Treasury clearing, retail expansion, and crypto, are poised to fuel future compounding. Despite a slightly premium valuation (~20x earnings), CME offers quality defensive exposure and strong fundamentals, making the recent dip a buying opportunity.

CME Group ( CME ) shares have had a rough time of late. This comes at an interesting time. CME closed 2025 as the best year in its history, its fourth consecutive year